The nation of Zimbabwe has declined a significant US healthcare agreement valued at $367m (£272m) over five years due to the United States' request for confidential information.
This move came to light following a official document dated December was leaked, indicating that President Emmerson Mnangagwa felt the deal was "skewed".
A government representative later explained that the United States was requesting biological samples for research and commercial gain but refused to share the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate process of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged more talks to secure a agreement suitable to both sides so the nation's critical HIV treatment initiative can be sustained.
Wider Context
This rejection comes after a comparable case in neighbouring Kenya, where a court suspended a related deal with the US after legal challenges were raised about the safety of citizens' medical information.
Since resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had managed aid for the American government, but Trump argued its expenditure was "wasteful" and his government was seeking government-to-government deals to enhance openness and accountability.
As per statements, Sixteen nations in Africa have so far signed these new health pacts, constituting over $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no corresponding promise of access to any medical innovations – like new medicines or tests – that might be developed from that provided information," his statement read.
"Put simply, our nation would provide the raw materials for scientific discovery with no assurance that the end products would be accessible to our citizens if a future disease outbreak arise."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were upending structures already established via the global organization.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This mechanism is intended to ensure that when a country contributes its information, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage continued discussions with our American counterparts on how future collaboration could be designed in a manner that honours the independence and dignity of both nations."
Health Experts Reaction
Medical experts stated it understood the official position, but recommended that talks should continue given that much of the nation's Aids initiatives depended on external financing.
"If technical issues arise, such as those involving information security or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," it said.
This impasse underscores the complex challenges between receiving much-needed foreign assistance and safeguarding national sovereignty in an ever more interconnected world.